

**Papua New Guinea
Support for Measles-Rubella Vaccine**

This Decision Letter sets out the Programme Terms

1. Country: Papua New Guinea			
2. Grant number: 19-PNG-09a-X; / 15-PNG-08d-Y			
3. Date of Decision Letter: 14 March 2019			
4. Date of the Partnership Framework Agreement (PFA): 29 November 2013			
5. Programme title: New Vaccine Support (NVS), Measles-Rubella Second Dose routine - strat 1			
6. Vaccine type: Measles-Rubella			
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED			
8. Programme duration¹: 2015 -2019			
9. Programme Budget (indicative): (subject to the terms of the PFA, if applicable)			
	2015-2018	2019	Total²
Programme Budget (US\$)	242,211 ³	35,000	277,211
10. Vaccine introduction grant (in US\$): Net disbursement of US\$ 122,816 on 14 July 2014			
11. Indicative Annual Amounts: (subject to the terms of PFA, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2015-2018	2019	
Number of Measles-Rubella vaccines doses			112,200
Annual Amounts (US\$)	242,211 ⁵		35,000
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable.			
14. Co-financing obligations: Gavi provides support only to costs equivalent to the measles component of MR second dose, with the country required to pay the remainder.			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

15. Operational support for campaigns: Net disbursement of US\$ 1,599,882 (2014 / 2017 / 2018)

16. Additional reporting requirements: Not applicable

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock, by end March; Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2019 15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable.

18. Other conditions:


Country has presented an official request to Gavi to switch from measles vaccine to measles- rubella vaccine for the routine second dose, with country funding the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.

	2019
Number of doses of vaccines for Measles Second Dose approved by Gavi.	112,200
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	34,333
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	53,646
Number of doses of Measles-Rubella vaccine to be funded by country.	58,554
Amount for Measles-Rubella vaccines to be funded by country in US\$ (excluding freight and insurance).	37,475

In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.

In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

14 March 2019